Results 231 to 240 of about 35,844 (248)

Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial

Lancet Oncology, The, 2020
Robert Coleman, Frcp, Dianne M Finkelstein, Carlos Henrique Barrios   +2 more
exaly  

Denosumab in patients with cancer—a surgical strike against the osteoclast

Nature Reviews Clinical Oncology, 2012
Janet E Brown
exaly  

10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension

Lancet Diabetes and Endocrinology,the, 2017
Henry Bone, Jacques P Brown, Roland D Chapurlat   +2 more
exaly  

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

Lancet, The, 2012
Fred Saad, Bertrand Tombal, Lawrence I Karsh   +2 more
exaly  

Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial

Lancet, The, 2015
Benjamin Z Leder, Hang Lee, Sherri-Ann M Burnett-Bowie   +2 more
exaly  

Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

Lancet, The, 2013
Hang Lee, Sherri-Ann M Burnett-Bowie, Benjamin Z Leder   +2 more
exaly  

Denosumab versus zoledronic acid in bone disease treatment of newly diagnosed multiple myeloma: an international, double-blind, double-dummy, randomised, controlled, phase 3 study

Lancet Oncology, The, 2018
Noopur S Raje, Evangelos Terpos, Ramón García-Sanz   +2 more
exaly  

Vertebral Fractures After Discontinuation of Denosumab: A Post Hoc Analysis of the Randomized Placebo-Controlled FREEDOM Trial and Its Extension

Journal of Bone and Mineral Research, 2018
Serge Ferrari, Richard Eastell, Michael McClung   +2 more
exaly  

Denosumab in patients with giant-cell tumour of bone: an open-label, phase 2 study

Lancet Oncology, The, 2010
David M Thomas,,, Fracp, Keith M Skubitz, J-Y Blay   +2 more
exaly  

Osteoprotegerin and Denosumab Stimulate Human Beta Cell Proliferation through Inhibition of the Receptor Activator of NF-κB Ligand Pathway

Cell Metabolism, 2015
Adolfo Garcia-Ocaña
exaly